DTA-2: Dopaminergic Therapy for Anhedonia - 2

Sponsor

Emory University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06075771

Collaborator

National Institute of Mental Health (NIMH) (NIH)

Enrollment

Location

Arms

Anticipated Duration (Months)

1.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks. Participants will complete lab tests, medical and psychiatric assessments, motivation and motor tasks, and MRI scans as part of the study. The total length of participation is approximately 10 to 12 weeks.

Condition or Disease	Intervention/Treatment	Phase
Anhedonia Depression	Drug: Carbidopa Levodopa Drug: Placebo	Phase 4

Detailed Description

Depression is a widespread disorder (lifetime prevalence >20%). Current antidepressant medications are effective for many patients; however, more than 30% fail to respond. Of the patients that do respond to treatment, some continue to suffer with primary symptoms of depression like an inability to experience pleasure, called anhedonia. In this regard, one biological pathway that may contribute to symptoms of depression and particularly anhedonia is inflammation.

The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Despite evidence of low dopamine function in patients with depression, the ability of existing dopaminergic therapies, like L-DOPA, to affect brain circuits in depression has yet to be explored. This study will help determine whether an FDA-approved medication, Sinemet (L-DOPA), might be used in the future to treat sub-groups of depressed individuals.

Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks. Participants will complete lab tests, medical and psychiatric assessments, motivation and motor tasks, and MRI scans as part of the study. The total length of participation is approximately 10 to 12 weeks.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

70 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

2:1 randomization to L-DOPA versus placebo2:1 randomization to L-DOPA versus placebo

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

Dopaminergic Therapy for Inflammation-Related Anhedonia in Depression - 2

Anticipated Study Start Date :

Nov 1, 2023

Anticipated Primary Completion Date :

Jan 1, 2027

Anticipated Study Completion Date :

Jan 1, 2027

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Carbidopa Levodopa Group Patients randomized to the Carbidopa Levodopa Group will receive one tablet per day of L-DOPA (150 mg levodopa administered with 37.5 mg carbidopa) for 4 weeks. Patients that respond after the initial 4 weeks will continue on the same dose for an additional 4 weeks to determine whether clinical response at the 150 mg dose is sustained over time compared to placebo. Patients that do not exhibit a clinical response (50% reduction in HAM-D scores from baseline) after 4-weeks on the 150 mg dose will escalate to 450 mg L-DOPA (three tablets per day of 150 mg levodopa administered with 37.5 mg carbidopa) and studied over an additional 4 weeks (8 weeks total in the study).	Drug: Carbidopa Levodopa Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day. Other Names: Sinemet, L-DOPA
Placebo Comparator: Placebo Group Participants will receive placebo tablet. Placebo-treated non-responders at 4 weeks will remain on placebo but with the same instructions to increase daily pill intake.	Drug: Placebo A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet. Other Names: Placebo tablet

Arm

Intervention/Treatment

Experimental: Carbidopa Levodopa Group

Patients randomized to the Carbidopa Levodopa Group will receive one tablet per day of L-DOPA (150 mg levodopa administered with 37.5 mg carbidopa) for 4 weeks. Patients that respond after the initial 4 weeks will continue on the same dose for an additional 4 weeks to determine whether clinical response at the 150 mg dose is sustained over time compared to placebo. Patients that do not exhibit a clinical response (50% reduction in HAM-D scores from baseline) after 4-weeks on the 150 mg dose will escalate to 450 mg L-DOPA (three tablets per day of 150 mg levodopa administered with 37.5 mg carbidopa) and studied over an additional 4 weeks (8 weeks total in the study).

Drug: Carbidopa Levodopa

Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day.

Other Names:

Sinemet, L-DOPA

Placebo Comparator: Placebo Group

Participants will receive placebo tablet. Placebo-treated non-responders at 4 weeks will remain on placebo but with the same instructions to increase daily pill intake.

Drug: Placebo

A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet.

Other Names:

Placebo tablet

Outcome Measures

Primary Outcome Measures

Change in depressive symptom severity measured by Hamilton Depression Rating Scale (HAM-D) [Baseline, weeks 1-4 post-intervention, weeks 5-8 post-intervention]
The HAM-D-17 is a 17-item, clinician administered scale, that rates severity of depression. Each item is rated on a scale 0-4 with higher scores indicating greater pathology.

Secondary Outcome Measures

Change in corticostriatal functional connectivity (FC) in reward circuits [Baseline, week 4 post-intervention, week 8 post-intervention]
Patients will undergo resting-state and task-based functional magnetic resonance imaging (fMRI) to calculate functional connectivity (FC) between the ventral striatum (VS) and ventromedial prefrontal cortex (vmPFC). FC is measured as continuous Z scores reflecting the correlation of activity between the brain regions. Higher FC Z scores reflect stronger connectivity.
Change in objective motivation assessed by Effort-Expenditure for Rewards Task (EEfRT) [Baseline, week 4 post-intervention, week 8 post-intervention]
The EEfRT is a widely used, multi-trial task in which participants are given an opportunity on each trial to choose between two different task difficulty levels in order to obtain monetary rewards. EEfRT will be used as an objective measure of motivation, and will be administered following MRI scans during the study. The EEfRT is reported as the percent of high effort trials selected. A higher percentage reflects higher motivation for effort expenditure.
Change in Inventory of Depressive Symptomatology- Self-Report (IDS-SR) [Baseline, weeks 1-4 post-intervention, weeks 5-8 post-intervention]
Anhedonia will be assessed from a subscale of the IDS-SR. Scores on this 3-question scale range from 0-9 with higher scores reflecting greater anhedonia.
Change in Snaith-Hamilton Pleasure Scale-Clinician (SHAPS-C) [Baseline, weeks 1-4 post-intervention, weeks 5-8 post-intervention]
The SHAPS-C is a clinician administered tool to assess symptoms of anhedonia. The SHAPS-C uses14 questions each rated on a Likert scale of 1-4, with higher scores reflecting greater pathology.
Change in Motivation and Pleasure-Self-Report (MAP-SR) [Baseline, weeks 1-4 post-intervention, weeks 5-8 post-intervention]
The MAP-SR will be used to capture self-reported aspects of anhedonia and reduced motivation. The scale uses 18 questions each rated on a Likert scale of 0-4, with higher scores reflecting greater pathology.

Eligibility Criteria

Criteria

Ages Eligible for Study:

25 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

1. willing and able to give written informed consent;
1. men or women, 25-55 years of age;
1. a primary diagnosis of DSM-V MD, current, as diagnosed by the SCID-V;
1. score of >10 on the PHQ-9 or HAM-D score ≥18;
1. off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, anxiolytics, and sedative hypnotics) for at least 4 weeks prior to baseline visit (8 weeks for fluoxetine)
1. CRP ≥2 mg/L,
1. PHQ-9 anhedonia score ≥2.

Exclusion Criteria:

1. history or evidence (clinical or laboratory) of an autoimmune disorder ;
1. history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection;
1. history of any type of cancer requiring treatment with more than minor surgery;
1. unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG and laboratory testing);
1. history of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; history or current bipolar disorder; history or current gambling disorder; substance abuse/dependence within 6 months of study entry (as determined by standardized clinician interview);
1. active suicidal plan as determined by a score >3 on item #3 on the HAM-D;
1. an active eating disorder (except for patients with binge eating disorder in whom binging is clearly associated with worsening of mood symptoms) ;
1. a history of a cognitive disorder or traumatic head injury involving loss of consciousness;
1. pregnancy or lactation,
1. use of gender affirming hormone therapy;
1. chronic use of non-steroidal anti-inflammatory agents (NSAIDS) (excluding 81mg of aspirin), glucocorticoid containing medications or statins;
1. use of NSAIDS, glucocorticoids, or statins at any time during the study;
1. urine toxicology screen is positive for drugs of abuse, n. any contraindication for MRI scanning;
1. intolerance, sensitivity or contraindication to carbidopa-levodopa (including history of narrow-angle glaucoma, melanoma, gastric and/or duodenal ulcers, bleeding disorders, or frequent migraines)